AMSTERDAM, April 11 (Reuters) - Dutch biotech firm Crucell CRCL.ASCRXL.O will be delisted from Euronext Amsterdam after the close of trading on Monday, following its takeover by U.S. healthcare company Johnson & Johnson (JNJ.N).
Crucell listed in Amsterdam in 2000 and its delisting concludes a tense takeover which was strongly resisted by some shareholders who said the offer price was too low. During this period, Crucell faced additional problems when one of its production plants was contaminated.
Below is an overview of recent news and analysis.
ANALYSIS European biotech power shifts to new firms [ID:nLDE71M1BO] Crucell CEO must deliver pipeline [ID:nLDE70K0SQ] Will J&J lower its bid for vaccine maker Crucell? [ID:nLDE7020JJ] The cost of a malaria-free world [ID:nLDE6BD0LZ] Crucell takes vaccine upperhand, but for how long? [ID:nLDE67G1M3]
NEWS Crucell can keep selling Quinvaxem [ID:nLDE7191UA] Crucell investor Van Herk to tender shares [ID:n7LDE7182L] Crucell investors back change for J&J takeover [ID:nLDE71707S] Crucell swings to full-year net loss [ID:nLDE71609E] Crucell resumes Korean vaccine production [ID:nLDE70C1UN] Crucell urges rebel investors to accept offer [ID:nLDE6B91E4] Key investor urges Crucell to drop J&J offer [ID:nLDE6961VU] J&J wins Crucell's backing for $2.4 billion bid [ID:nLDE695056] J&J aims to buy vaccine maker Crucell for $2.3 bln [ID:nLDE68G076]
(Compiled by Aaron Gray-Block)